The separation of HER2-enriched cancers from other breast cancers was successful, with the following accuracies: HER2-enriched vs. luminal A, 83.3 % (Fisher/based on COM and RLM features); and HER2-enriched vs. all others, 90.1 % (Fisher/based on RLM and COM features). The gene discussed is ERBB2; the disease is breast cancer.